Return to search results
Rivastigmine tartrate
Rivastigmine Tartrate is a generic prescription medication available as oral capsules in strengths of 1.5mg, 3mg, 4.5mg, and 6mg (base equivalent). It acts as a cholinesterase inhibitor to help manage symptoms of Alzheimer's disease and related dementias. Manufactured by Macleods Pharmaceuticals Limited. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Rivastigmine Tartrate is a generic prescription medication available as oral capsules in strengths of 1.5mg, 3mg, 4.5mg, and 6mg (base equivalent). It acts as a cholinesterase inhibitor to help manage symptoms of Alzheimer's disease and related dementias. Manufactured by Macleods Pharmaceuticals Limited. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Rivastigmine tartrate",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Rivastigmine tartrate — ANDA 077130 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077130"
}
]
|
| identifier | ANDA077130 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"drug-safety",
"fda",
"pharmaceuticals",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Rivastigmine tartrate |
